top of page

Modality profile: Bi-Specifics and cytokines at #ASCO23

Xencor CEO Bassil Dahiyat walks us through the idea behind bi-specific antibodies and cytokines in cancer research.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page